Abstract Number: 1251 • 2014 ACR/ARHP Annual Meeting
Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases
Background/Purpose Anti-TNF-α therapy may be useful in cases of uveitis refractory to standard synthetic immunosuppressive drugs. Infliximab (IFX) and adalimumab (ADA) are the biologic agents…Abstract Number: 1460 • 2013 ACR/ARHP Annual Meeting
10 Years Of Treat-To-Target Therapy In Rheumatoid Arthritis Patients (the BeSt study): Clinical and Radiological Outcomes
Background/Purpose: Long term studies with treat-to-target therapy are essential to guide treatment strategies. We report on a study that compared clinical and radiological outcomes of…Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…Abstract Number: 1469 • 2013 ACR/ARHP Annual Meeting
Therapeutic Strategy In Patients With Rheumatoid Arthritis and Insufficient Response To a 1st Anti-TNF: Results of the Multicenter Randomized Controlled “ROC” Trial
Background/Purpose: TNF inhibitors often represent the 1st biologic prescribed to patients with rheumatoid arthritis (RA). Approximately one third of patients fail to respond. However, therapeutic…Abstract Number: 1344 • 2013 ACR/ARHP Annual Meeting
Optimal Rheumatoid Arthritis Patient Selection For Biological Treatment From Pharmacoeconomic Perspectives Based On The Institute Of Rheumatology, Rheumatoid Arthritis (IORRA) Cohort
Background/Purpose: With the recent introduction of biological DMARDs, the economic burden of rheumatoid arthritis (RA) treatment has increased. Previous studies evaluated the cost-effectiveness of biologics,…Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…Abstract Number: 997 • 2013 ACR/ARHP Annual Meeting
Does Biologic Treatment For Rheumatoid Arthritis Offset Health Care Costs In Patients With Rheumatoid Arthritis? An Instrumental Variable Approach Using Administrative Data
Background/Purpose: Expenditure on biologic therapies for rheumatoid arthritis (RA) accounts for the highest pharmaceutical spending in many western healthcare systems. Given their clinical benefit with…Abstract Number: 998 • 2013 ACR/ARHP Annual Meeting
Adequacy Of Drug Coverage and Cost-Sharing For Medicare Beneficiaries With Rheumatoid Arthritis
Background/Purpose : Biologic and non-biologic disease-modifying anti-rheumatic drugs (DMARDs) significantly reduce pain, disability and mortality in rheumatoid arthritis (RA). We evaluated how well RA drugs…Abstract Number: 495 • 2013 ACR/ARHP Annual Meeting
The Impact Of Inadequate Response To Prior Biologic Agents On Abatacept Drug Retention In Rheumatoid Arthritis Patients. A Pan-European Analysis Of RA Registries
Background/Purpose: In rheumatoid arthritis (RA), abatacept (ABA) may be used in biologic naïve patients (pts) or after failure to an anti-TNF or other biologic agents…Abstract Number: 2808 • 2013 ACR/ARHP Annual Meeting
Favorable Outcome Of Hepatitis E Virus Infection In Patients With Inflammatory Arthritides Treated With Immunosupressants
Background/Purpose: In inflammatory rheumatic diseases, the prevalence, clinical presentation and outcome of hepatitis E, an ubiquitous viral infection, remain unknown. We therefore addressed these issues…Abstract Number: 328 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients Who Switch Biologic Therapy Within The First Two Years: Results From a Large US Registry Population
Background/Purpose: The use of biologic therapy in psoriatic arthritis (PsA) has altered the disease course and has been shown to reduce disease activity. Data comparing…Abstract Number: 2687 • 2013 ACR/ARHP Annual Meeting
Very High Remission Rates Are Achieved By Methotrexate and Intraarticular Glucocorticoids Independent Of Induction Therapy With Adalimumab; Year 2 Clinical Results Of An Investigator-Initiated Randomised, Controlled Clinical Trial Of Early, Rheumatoid Arthritis (OPERA)
Background/Purpose: In a double-blind placebo-controlled 2-year investigator-initiated trial of patients with early rheumatoid arthritis (RA), we investigated if additional adalimumab (ADA) for 1 year on…Abstract Number: 2378 • 2013 ACR/ARHP Annual Meeting
Safety Of Mavrilimumab In Cynomolgus Monkeys: Relevance Of Nonclinical Findings In Lung To Human Safety
Background/Purpose: GM-CSF plays a central role in the pathogenesis of rheumatoid arthritis (RA) through the activation, differentiation, and survival of macrophages and neutrophils. Mavrilimumab (CAM-3001)…Abstract Number: 2360 • 2013 ACR/ARHP Annual Meeting
Incidence Of Diabetes and Effect Of Etanercept and Adalimumab On HbA1c Over 1 Year: Data From a Randomised Trial In Patients With Rheumatoid Arthritis
Background/Purpose: Inflammation such as that which occurs in rheumatoid arthritis (RA) is associated with insulin resistance and risk of diabetes mellitus (DM). Some DMARDs including…Abstract Number: 2316 • 2013 ACR/ARHP Annual Meeting
Anti-Human TNF-Alpha Domain Antibody Construct, CEP-37247/Placulumab, Is As Efficacious As Other Leading TNF-Alpha-Blockade Therapies in a Humanized Mouse Model of Rheumatoid Arthritis
Background/Purpose: The cytokine tumor necrosis factor (TNF)alpha is a potent pro-inflammatory mediator involved in several autoimmune diseases including rheumatic arthritis and for over a decade…
ACR Meeting Abstracts